Our Services
Medical Information
Helpful Resources
Published on: 10/26/2026
Stopping duloxetine suddenly can trigger discontinuation symptoms such as dizziness, nausea, headache, irritability, insomnia, vivid dreams, and the electric shock sensations often called brain zaps, which commonly begin within one to three days and ease over one to two weeks. How intense withdrawal feels depends on your dose, how long you took the medication, and how quickly you reduce it, so there are several important factors to consider below. Clinicians generally advise a slow taper, lowering the dose in small steps over weeks or months using smaller capsule strengths or spaced dosing, instead of quitting all at once. Because withdrawal can closely mimic a relapse of depression or anxiety, and a few symptoms deserve prompt medical review, the complete details below are worth reading before you change anything. If you are unsure whether what you are feeling is withdrawal, a returning condition, or something unrelated, a free, instant, online symptom check can help you sort out your symptoms and decide on sensible next steps.
Last reviewed for medical accuracy: 10/22/2026
Duloxetine (Cymbalta) is a serotonin-norepinephrine reuptake inhibitor (SNRI) commonly prescribed for depression, anxiety, fibromyalgia, and certain pain disorders. When you stop duloxetine suddenly—or too quickly—you may experience duloxetine withdrawal symptoms, also known as discontinuation syndrome. Understanding what to expect and how a gradual taper can help you manage these effects is essential for a safer, more comfortable transition off the medication.
Duloxetine works by increasing serotonin and norepinephrine levels in the brain. Over weeks or months, your nervous system adapts to these higher levels. If duloxetine is reduced too quickly, neurotransmitters can dip below your brain’s new “baseline,” triggering withdrawal symptoms.
Key factors that influence withdrawal risk:
Symptoms of duloxetine withdrawal can range from mild to intense and typically begin within 24–72 hours of the last dose. They often peak around one to two weeks and gradually improve over several weeks. Some people, however, report lingering symptoms for months.
Physical symptoms:
Emotional and cognitive symptoms:
Less common but more distressing symptoms:
While everyone’s timeline is unique, a general pattern often emerges:
If symptoms worsen or persist beyond a few months, discussing long-term management strategies with a healthcare provider is crucial.
A carefully planned taper schedule is the most effective way to minimize duloxetine withdrawal. While individual plans will vary, these general principles apply:
Sample taper outline for someone on 60 mg daily (example only—always consult your doctor):
In addition to a formal taper plan, lifestyle adjustments can ease symptoms:
Most withdrawal symptoms are uncomfortable but not life threatening. However, contact a healthcare professional immediately if you experience:
For non-urgent questions or to gauge the severity of your symptoms, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you decide whether to seek in-person care.
Mood symptoms can be especially unsettling. Techniques to help include:
Open communication with your doctor or nurse practitioner is key:
Once you’ve successfully tapered off duloxetine, consider:
Always discuss any concerns or unusual symptoms with a qualified healthcare professional. If you experience anything life threatening or seriously concerning, seek immediate medical care or call emergency services. Continuous partnership with your doctor will help ensure the safest, most effective approach to discontinuing duloxetine.
(References)
* Domperidone. Drugs and Lactation Database (LactMed®). 2006. PMID: 30000430.
* Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87(4):195-203. doi: 10.1159/000491524. Epub 2018 Jul 17. PMID: 30016772.
* Zorn A, Linn S, Jenkinson M, Neher JO, Safranek S, Kelsberg G. Is ketamine effective and safe for treatment-resistant depression? J Fam Pract. 2021 Apr;70(3):E1-E3. doi: 10.12788/jfp.0176. PMID: 34314342.
* Zhang S. Chemotherapy-induced peripheral neuropathy and rehabilitation: A review. Semin Oncol. 2021 Jun;48(3):193-207. doi: 10.1053/j.seminoncol.2021.09.004. Epub 2021 Sep 22. PMID: 34607709.
* Yajima M, Sugimoto M, Sugimura YK, Takahashi Y, Kato F. Acetaminophen and pregabalin attenuate central sensitization in rodent models of nociplastic widespread pain. Neuropharmacology. 2022 Jun 1;210:109029. doi: 10.1016/j.neuropharm.2022.109029. Epub 2022 Mar 16. PMID: 35305985.
* Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17. PMID: 36253442; PMCID: PMC9812779.
* Yeh TC, Correll CU, Yang FC, Chen MH, Tseng PT, Hsu CW, Carvalho AF, Stubbs B, Thompson T, Chu CS, Yu CL, Il Shin J, Yang SN, Tu YK, Liang CS. Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment. Asian J Psychiatr. 2023 Jan;79:103375. doi: 10.1016/j.ajp.2022.103375. Epub 2022 Nov 26. PMID: 36470132.
* Birkinshaw H, Friedrich CM, Cole P, Eccleston C, Serfaty M, Stewart G, White S, Moore RA, Phillippo D, Pincus T. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Cochrane Database Syst Rev. 2023 May 10;5(5):CD014682. doi: 10.1002/14651858.CD014682.pub2. Epub 2023 May 10. PMID: 37160297; PMCID: PMC10169288.
* Migliorini F, Maffulli N, Eschweiler J, Baroncini A, Bell A, Colarossi G. Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis. J Orthop Surg Res. 2023 Jul 17;18(1):504. doi: 10.1186/s13018-023-03995-z. Epub 2023 Jul 17. PMID: 37461044; PMCID: PMC10351165.
* McGowan K, Poos S, Vo N. Severe bullous pemphigoid with excoriation disorder. BMJ Case Rep. 2022 Sep 5;15(9). doi: 10.1136/bcr-2022-250285. Epub 2022 Sep 5. PMID: 39901397; PMCID: PMC9445805.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.